* 泰国富豪谢氏家族旗下制药公司--中国生物制药1177.HK周一早盘涨幅扩大至3.7%。
* 该公司稍早公告称，维特柯妥拜单抗正在开展用于治疗三线及以上CLDN18.2阳性的局部晚期或转移性胃及胃食管交界部腺癌的III期注册临床试验(LM302-03-101)，已完成患者入组。
* 中国生物制药今年迄今涨7.9%，同期恒生指数.HSI上扬5.2%。
* 恒⽣⽣物科技指数.HSBIO盘中一度升2.9%。（完）
更多股市简讯请点选CN-CMN-HOT
(发稿 徐凯文；审校 杨淑祯)
((kaiwen.xu@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.